Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01136876 · ClinicalTrials.gov registry record · Phase 4

Kidney Damage in Patients With Moderate Fall in eGFR

A Phase 4 study, sponsored by Bracco Diagnostics.

Completed
Registry status
Phase 4
Development phase
57
Enrollment target

NCT01136876: Completed Phase 4 study, sponsored by Bracco Diagnostics.

NCT01136876 is a Phase 4 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 57 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01136876, a Phase 4 study, has completed, sponsored by Bracco Diagnostics.

COMPLETED
Registry status
Phase 4
Development phase
57 participants
Enrollment target

Study Summary

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

Primary Outcome

Mean change from baseline values for serum NGAL at 2,4,6,24,48, and 72 hours, and urine NGAL at 2,4,6,24, and 48 hours following the administration of contrast media.

Interventions

  • DRUG Iopamidol
  • DRUG Iodixanol-320

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2010-11
Est. Completion 2012-11
Phase Phase 4
Bracco Diagnostics

37 total trials

What the finished NCT01136876 record still lists

NCT01136876 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 2 interventions - of which Iopamidol is the first listed.

NCT01136876 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01136876 about?

NCT01136876 is a clinical study titled "Kidney Damage in Patients With Moderate Fall in eGFR". To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

What is the current status of trial NCT01136876?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 2010-11. Estimated completion is 2012-11.

What interventions are being tested in trial NCT01136876?

The interventions under investigation include: Iopamidol (DRUG), Iodixanol-320 (DRUG).

Who is sponsoring clinical trial NCT01136876?

This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01136876's enrollment target sits among peer trials

57 1209th of 2000 higher than 788 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01136876, the US trial registry maintained by the National Library of Medicine. NCT01136876 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.